Hemab Therapeutics has announced the closing of an oversubscribed Series B financing.
The round was led by Access Biotechnology with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity. All current investors including HealthCap,
You have read all your free articles, to continue reading subscribe to read the rest of this content.